Logo

BMS Presents Results of Opdivo (nivolumab) + CT or Yervoy (ipilimumab) in P-III CheckMate -648 Trial for Unresectable Advanced or Metastatic ESCC at ASCO 2021

Share this

BMS Presents Results of Opdivo (nivolumab) + CT or Yervoy (ipilimumab) in P-III CheckMate -648 Trial for Unresectable Advanced or Metastatic ESCC at ASCO 2021

Shots:

  • The P-III CheckMate -648 trial evaluating Opdivo + CT or Opdivo (3 mg/kg- q2w) + Yervoy (1 mg/kg- q6w up to 24mos.) in patients with unresectable advanced or metastatic ESCC
  • Results: Both combinations showed OS benefits over CT in PD-L1 positive & all-randomized populations- m-OS for Opdivo + CT (13.7 vs 9.1 mos. & 13.2 vs 10.7 mos.) & for Opdivo + CT (3.7 vs 9.1 mos. & 2.8 vs 10.7 mos.); mDoR (8.4 vs 11.8 mos.) & 5.7 mos. for CT alone; ORR (53% vs 35%) & 20% for CT alone
  • Additionally- Opdivo + CT showed improvement in PFS with an m-PFS (6.9 vs 4.4 mos.) while Opdivo + Yervoy failed to meet its 1EPs of PFS- safety profiles were consistent with previously reported for other tumors

  Ref: Businesswire | Image: BMS

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions